Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple System Atrophy Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Autonomic Nervous System and Obesity

NCT00179023
View directory record Official record
Conditions
OBESITY, HYPERTENSION, PURE AUTONOMIC FAILURE, SHY-DRAGER SYNDROME
Interventions
Trimethaphan, Pseudoephedrine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Jul 22, 2026, 5:02 AM EDT
Enrolling by invitation No phase listed Observational

AB-1005 Long-Term Follow-up Study

NCT07081841
View directory record Official record
Conditions
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant
Interventions
Observation
Other
Lead sponsor
AskBio Inc
Industry
Eligibility
Not listed
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2038
U.S. locations
2
States / cities
San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 22, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 22, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

NCT02295748
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Deflazacort
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
4 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Jul 22, 2026, 5:02 AM EDT
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 5:02 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies
Interventions
[18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose
Drug
Lead sponsor
Daniel Claassen
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 22, 2026, 5:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Inherited Retinal Degenerative Disease Registry

NCT02435940
View directory record Official record
Conditions
Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2037
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health

NCT04001088
View directory record Official record
Conditions
Menopause
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Lallemand Health Solutions
Industry
Eligibility
40 Years to 59 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
Lake Worth, Florida • Port Saint Lucie, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 22, 2026, 5:02 AM EDT
Withdrawn Phase 2 Interventional

Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis

NCT02011451
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
95% Pure ECGC capsules 200mg, Placebo Comparator:
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Jul 22, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy

NCT00227266
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Valproic Acid and Levocarnitine, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Baltimore, Maryland • Detroit, Michigan • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jul 22, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

Finding the Optimum Regimen for Duchenne Muscular Dystrophy

NCT01603407
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Prednisone, Deflazacort
Drug
Lead sponsor
University of Rochester
Other
Eligibility
4 Years to 7 Years · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Jul 22, 2026, 5:02 AM EDT
Recruiting Not applicable Interventional

CPAP for the Treatment of Supine Hypertension

NCT05489575
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Supine Hypertension, Neurogenic Orthostatic Hypotension
Interventions
Active CPAP, Sham CPAP, Sleeping in a head-up tilt (HUT) position
Device · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional

Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

NCT04004065
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Vesleteplirsen
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 21 Years · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
11
States / cities
Sacramento, California • Farmington, Connecticut • Gulf Breeze, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 22, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy

NCT01540409
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
AVI-4658 (Eteplirsen)
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 13 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Long Beach, California • Gainesville, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 22, 2026, 5:02 AM EDT
Recruiting Phase 1 Interventional

Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies

NCT06683365
View directory record Official record
Conditions
Multiple System Atrophy, Parkinsons Disease
Interventions
Sural Nerve Graft to the Substantia Nigra, Sham surgery
Procedure
Lead sponsor
Craig van Horne, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 5:02 AM EDT
Active, not recruiting Phase 1 Interventional

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic

NCT02726711
View directory record Official record
Conditions
Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension
Interventions
Trimethaphan, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
40 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 22, 2026, 5:02 AM EDT
Completed No phase listed Observational

Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate

NCT02307877
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Jul 22, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls

NCT01523964
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Testing with EIM
Other
Lead sponsor
Dart Therapeutics. LLC
Other
Eligibility
3 Years to 12 Years · Male only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2013 · Synced Jul 22, 2026, 5:02 AM EDT
Completed No phase listed Observational

Diagnosis and Natural History Study of Patients With Neurological Conditions

NCT00001549
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Movement Disorder, Multiple System Atrophy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 5:02 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT04095793
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Jul 22, 2026, 5:02 AM EDT
Terminated Not applicable Interventional

A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation

NCT03783884
View directory record Official record
Conditions
Ventilator Induced Diaphragm Dysfunction
Interventions
Lungpacer Diaphragm Pacing Therapy
Device
Lead sponsor
Lungpacer Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
22
States / cities
Stanford, California • Aurora, Colorado • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Jul 22, 2026, 5:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ATX-01 in Participants With DM1

NCT06300307
View directory record Official record
Conditions
Myotonic Dystrophy 1
Interventions
ATX-01, Placebo
Drug
Lead sponsor
ARTHEx Biotech S.L.
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 22, 2026, 5:02 AM EDT
Completed No phase listed Observational

Cognitive Impairement In Frontotemporal Dementia

NCT03452956
View directory record Official record
Conditions
Frontotemporal Degeneration, Progressive Supranuclear Palsy, Multiple System Atrophy
Interventions
None-Observation Only
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
997 participants
Timeline
2003 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Jul 22, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhance Wellness for Individuals With Long-Term Physical Disabilities

NCT02815878
View directory record Official record
Conditions
Multiple Sclerosis, Muscular Dystrophy, Post-polio Syndrome, Spinal Cord Injury
Interventions
Enhance Wellness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Jul 22, 2026, 5:02 AM EDT